Puma Biotechnology, Inc. (PBYI) Stock Analysis

Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript

Fri, August 14, 2026 at 2:27 PM UTC 2 min read

Puma Biotechnology (PBYI) reported its Q2 2026 earnings, showcasing a significant increase in revenue driven by strong sales of its flagship drug, Neratinib. The company's positive financial performance and updated guidance suggest a robust market position and potential for future growth, which is encouraging for investors. Additionally, ongoing clinical trials may further enhance the company's portfolio, making it a stock to watch in the biotech sector.

Read full article →

Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline

Thu, July 30, 2026 at 2:00 PM UTC 3 min read

Puma Biotechnology (PBYI) is anticipated to report a decline in Q2 earnings, reflecting ongoing challenges in revenue generation and market competition. This expected downturn could raise concerns among investors regarding the company's growth prospects and financial stability. As Puma continues to navigate a competitive landscape, stakeholders will be closely monitoring the earnings report for insights into future performance and strategic direction.

Read full article →